Citigroup
RXRX icon

Citigroup’s Recursion Pharmaceuticals RXRX Stock Holding History

Citigroup’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.17M Buy
864,403
+681,793
+373% +$2.27M ﹤0.01% 2549
2026
Q1 		$561K Buy
182,610
+12,323
+7% +$47.6K ﹤0.01% 3479
2025
Q4 		$696K Buy
170,287
+103,886
+156% +$515K ﹤0.01% 3374
2025
Q3 		$324K Sell
66,401
-148,346
-69% -$779K ﹤0.01% 3775
2025
Q2 		$1.09M Sell
214,747
-444,702
-67% -$2.18M ﹤0.01% 3142
2025
Q1 		$3.49M Buy
659,449
+158,461
+32% +$1.16M ﹤0.01% 2236
2024
Q4 		$3.39M Buy
500,988
+310,236
+163% +$2.09M ﹤0.01% 2348
2024
Q3 		$1.26M Buy
190,752
+87,142
+84% +$625K ﹤0.01% 3074
2024
Q2 		$777K Sell
103,610
-697,577
-87% -$6.08M ﹤0.01% 3080
2024
Q1 		$7.99M Buy
801,187
+396,334
+98% +$4.41M 0.01% 1389
2023
Q4 		$3.99M Sell
404,853
-65,659
-14% -$468K ﹤0.01% 1735
2023
Q3 		$3.6M Buy
470,512
+293,174
+165% +$2.92M ﹤0.01% 1607
2023
Q2 		$1.32M Sell
177,338
-510,887
-74% -$3.57M ﹤0.01% 2602
2023
Q1 		$4.59M Buy
688,225
+455,398
+196% +$3.61M ﹤0.01% 1547
2022
Q4 		$1.8M Buy
232,827
+71,267
+44% +$699K ﹤0.01% 2124
2022
Q3 		$1.72M Buy
161,560
+149,260
+1,213% +$1.51M ﹤0.01% 2265
2022
Q2 		$100K Sell
12,300
-2,599
-17% -$17.4K ﹤0.01% 4225
2022
Q1 		$106K Sell
14,899
-229,458
-94% -$2.44M ﹤0.01% 4387
2021
Q4 		$4.19M Buy
244,357
+199,063
+439% +$3.75M ﹤0.01% 1967
2021
Q3 		$1.04M Buy
45,294
+44,288
+4,402% +$1.26M ﹤0.01% 3051
2021
Q2 		$37K Buy
+1,006
New +$29.8K ﹤0.01% 4961

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup's RXRX Position: Q2 2026 in Review

Citigroup increased its Recursion Pharmaceuticals (RXRX) stake by 373% in Q2 2026, buying an estimated $2.27M and bringing the position to 864,403 shares worth $3.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2549.

Citigroup first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $7.99M in Q1 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Citigroup held 864,403 shares of Recursion Pharmaceuticals worth $3.17M as of Q2 2026.
  • Citigroup bought 681,793 Recursion Pharmaceuticals shares in Q2 2026, an estimated $2.27M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2549 holding.
  • Citigroup first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Citigroup's Recursion Pharmaceuticals position peaked at $7.99M in Q1 2024.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.